Hadron Energy (HDRN) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
5 Oct, 2026Executive summary
Newly formed blank-check vehicle completed a $200.0 million IPO; no business-combination target had been selected by September 30, 2024.
Q3 net income was $610,950, primarily reflecting $989,729 of Trust Account interest income, partly offset by operating costs and warrant fair-value expense.
Financial highlights
Q3 operating expenses were $213,755; warrant fair-value expense was $165,080; Trust Account interest income was $989,729 and operating-account interest was $56.
From inception through September 30, net income was $546,549 on zero revenue, with operating expenses of $278,157.
September 30 total assets were $203.36 million, including $200.99 million in the Trust Account and $2.01 million in cash outside it.
Outlook and guidance
No target had been selected or substantive target discussions undertaken; operating revenue is expected only after a business combination.
The initial business combination must be completed within 21 months of the August 30, 2024 IPO closing; management assessed liquidity as sufficient for at least one year from financial-statement issuance.
Public-company compliance and acquisition due-diligence costs are expected to increase.
Latest events from Hadron Energy
- Higher costs cut Q1 net income; merger closing hinges on cash, approvals and redemptions.HDRN
Q1 2026 - A $250 million blind-pool IPO pairs a 21-month deadline with steep dilution and conflicts.HDRN
Registration filing - A $250 million SPAC raise pairs a 24-month acquisition search with substantial dilution and conflicts.HDRN
Registration filing - Trust interest drove SPAC income as the microreactor target remained loss-making and pre-commercial.HDRN
Q4 2025 - Trust interest lifted Q1 profit as target search and going-concern risks persist.HDRN
Q1 2025 - 25M-unit IPO filing amended solely to add exhibits, with a 3.75M-unit option.HDRN
Registration filing - Trust income drove earnings, but no target and limited operating cash sustain execution risk.HDRN
Q2 2025 - $250M SPAC, no target selected, 24-month deadline and material dilution risks.HDRN
Registration filing - A microreactor commercialization plan meets a large resale overhang and acute funding risk.HDRN
Registration filing